Breaking News

Kite Pharma to Evaluate Cellares’ Automated Manufacturing Platform

Will assess viability of the Cell Shuttle as a future manufacturing option for Kite.

Author Image

By: Charlie Sternberg

Associate Editor

Kite Pharma, a Gilead Company, has announced plans to evaluate Cellares’ automated manufacturing platform, the Cell Shuttle. The data generated in this proof-of-concept evaluation will be utilized to assess viability of the Cell Shuttle as a future manufacturing option for Kite. “This agreement with Kite allows the unique capabilities of our Cell Shuttle platform to be potentially utilized by Kite in the future and reinforces Cellares’ position as a cell therapy manufacturer with advan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters